HOME >> BIOLOGY >> NEWS
Marker predicts pancreatic cancer outcome after surgery, Jefferson surgeon finds

A team of researchers, led by surgeons at the Kimmel Cancer Center at Jefferson in Philadelphia, has found further evidence supporting the ability of a protein to predict how well a patient with advanced pancreatic cancer will do after surgery, chemotherapy and radiation. The levels of the protein CA 19-9 in the blood can be used to determine the need for further therapy, they say.

Adam Berger, M.D., assistant professor of surgery at Jefferson Medical College of Thomas Jefferson University, and his co-workers examined CA 19-9 levels and the survival of 385 patients with advanced pancreatic cancer who were treated with surgery and subsequent chemotherapy and radiation. They found that those patients whose post-operative CA 19-9 level exceeded 180 U/ml did much worse than those with lower levels.

In fact, at least half of those whose CA 19-9 level was higher than 180 U/ml lived for approximately nine months, while half of those whose levels were 180 or below lived more than twice as long, about 21 months. After three years, about 30 percent of those with levels 180 or under were still alive, while virtually none of the patients with levels above 180 remained alive. He reports his teams findings June 23, 2007 at the semi-annual meeting of the Radiation Therapy Oncology Group (RTOG) in Philadelphia.

We think that it is a very sensitive predictor of response to chemotherapy and radiation after surgery, says Dr. Berger.

The main goal of the multicenter trial was to compare pancreatic cancer surgery patients who received two different types of chemotherapy 5FU or gemcitabine along with radiation. It was designed to look at CA 19-9 levels and survival after surgery as a secondary goal. Patients submitted blood samples prior to chemotherapy, which were analyzed for CA 19-9. Overall, 385 patients had levels that could be analyzed.

According to Dr. Berger, a post-surgery CA 19-9 level of 180 or less translated to a 72
'"/>

Contact: Steven Benowitz
Steven.Benowitz@jefferson.edu
215-955-6300
Thomas Jefferson University
22-Jun-2007


Page: 1 2

Related biology news :

1. Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers
2. Markers found for bacterial vaginosis
3. Markers of brain cell development may help success of stem cell transplants
4. Gene predicts better outcome as cortex normalizes in teens with ADHD
5. Major study predicts grim future for Europes seas
6. FDG-PET imaging clearly predicts lung cancer patients response to chemotherapy
7. NASA predicts nongreen plants on other planets
8. Gene profiling predicts resistance to breast cancer drug Herceptin
9. Mathematical model predicts cholera outbreaks
10. New test predicts blood cancers sensitivity to experimental cancer drug
11. Blood test predicts cardiac events and death in heart patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... ... voice recognition biometrics market to grow at a CAGR of 19.36% ... present scenario and the growth prospects of the global voice recognition ... considers the revenue generated from the sales of voice recognition biometrics ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... be safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and ... previous two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on ...
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... 24, 2017  Driven by consumers, preference towards ... the fastest growing categories, finds the recently published ... Personal Care: Multi-regional Market Analysis and Opportunities ... firm Kline. "Biotechnology actives are derived ... more effective for skin and hair care applications," ...
Breaking Biology Technology:
Cached News: